Abstract 111P
Background
Advanced stage colorectal cancer therapy shows positive progress by increasing overall survival (OS). Mainstay treatment still uses cytotoxic agents and oxaliplatin which results in an average survival of 18 months when combined with 5-Fluorouracil (5-FU) or capecitabine. This study aims to determine the effectiveness and safety of the use of FOLFOX and XELOX chemotherapy in advanced stage colorectal cancer patients using a meta-analysis study.
Methods
This is a meta-analysis study comparing only the Randomized Controlled Trial (RCT) study using FOLFOX and XELOX chemotherapy in patients with metastatic colorectal cancer taken from PubMed, EMBASE and The Cochrane Library using keywords: Capecitabine, FOLFOX, XELOX and metastatic colorectal.
Results
9 journals were included in the inclusion criteria and were followed by a meta-analysis study. A total of 5,873 patients were obtained with the number of groups given FOLFOX of 3,034 and 2,839 in the group given XELOX. The analysis doesn’t show evidence of publication bias in the forest plot. The results of the analysis of Progress Free Survival (PFS) found no significant heterogeneity (OR = 1.09, 95% CI: 0.97-1.23, p = 0.14), the Overall Survival (OS) analysis also did not obtain heterogeneity (OR = 0.98, 95% CI : 0.87-1.10, p = 0.77). Overall Response Rate (ORR) there were no significant differences in the two groups. All studies gave grade 3 and 4 toxicity. The results of the combined analysis showed thrombocytopenia, Hand Foot Syndrome (HFS) and diarrhea in the XELOX group were significantly higher.
Conclusions
The effectiveness of XELOX and FOLFOX found no significant differences. However, the safety of the XELOX group showed significantly more side effects. Keywords: FOLFOX, XELOX, Advanced Stage Colorectal Cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session